Neuropeptide-containing nerve fibres in the human parotid gland: a semiquantitative analysis using an antibody against protein gene product 9.5.
The occurrence and distribution of neuropeptide-containing fibres in the human parotid gland were examined by the peroxidase-antiperoxidase method with attention to the quality of fixation and the condition of patients. Many fibres immunoreactive for neuropeptide Y (NPY) and vasoactive intestinal polypeptide (VIP) and a moderate number of galanin-positive (GAL) fibres were distributed around the acini. A moderate number of NPY and VIP fibres were distributed around the intercalated ducts. The semiquantitative mean densities (+/- SD) of periacinar NPY, VIP and GAL fibres expressed as a percentage of the total protein gene product (PGP) 9.5 immunoreactive fibres were 75.62 +/- 7.25%, 70.52 +/- 9.33% and 41.76 +/- 5.45%, respectively, whereas those of substance P (SP), calcitonin gene-related peptide (CGRP) and FMRF amide (FMRF) fibres were below 10%. The mean densities of NPY and VIP fibres around the intercalated ducts expressed as the percentage of PGP 9.5 fibres associated with these ducts were 52.37 +/- 6.19% and 59.62 +/- 7.02% respectively. Those of SP, CGRP, GAL, and FMRF fibres were below 10%. The densities of NPY, VIP, SP, CGRP, GAL and FMRF fibres around the striated and excretory ducts were also below 10%. In the vasculature, NPY fibres were the most prominent. Similarly, the mean density of perivascular NPY fibres was 93.76 +/- 2.03%. No somatostatin or leucine or methionine enkephalin immunoreactivity was detected around the acini, duct system or blood vessels. These findings suggest that, in this gland, the periacinar NPY, VIP and GAL fibres may participate in regulating the synthesis of saliva and its secretion and that perivascular peptidergic fibres, especially NPY fibres, may be involved in controlling local blood flow.
Matsuda
H
H
Department of Otorhinolaryngology, Yokohama City University School of Medicine, Japan.
Kusakabe
T
T
Kawakami
T
T
Nagahara
T
T
Takenaka
T
T
Tsukuda
M
M
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015740:Calcitonin Gene-Related Peptide / Q000032:analysis; D004743:Enkephalin, Leucine / Q000032:analysis; D004744:Enkephalin, Methionine / Q000032:analysis; D019835:FMRFamide; D005260:Female; D019004:Galanin / Q000032:analysis; D006801:Humans; D008297:Male; D008875:Middle Aged; D009412:Nerve Fibers / Q000737:chemistry*; D009419:Nerve Tissue Proteins / Q000032:analysis*; D009478:Neuropeptide Y / Q000032:analysis; D009479:Neuropeptides / Q000032:analysis; D010306:Parotid Gland / Q000294:innervation*; D013004:Somatostatin / Q000032:analysis; D013373:Substance P / Q000032:analysis; D013869:Thiolester Hydrolases / Q000032:analysis* / Q000276:immunology; D043222:Ubiquitin Thiolesterase; D014660:Vasoactive Intestinal Peptide / Q000032:analysis
D009419:Nerve Tissue Proteins; D009478:Neuropeptide Y; D009479:Neuropeptides; D013373:Substance P; D014660:Vasoactive Intestinal Peptide; D013004:Somatostatin; D004744:Enkephalin, Methionine; D004743:Enkephalin, Leucine; D019835:FMRFamide; D019004:Galanin; D013869:Thiolester Hydrolases; D043222:Ubiquitin Thiolesterase; D015740:Calcitonin Gene-Related Peptide